Key result
Diabetic nephropathy is linked to significantly elevated Lp(a) and prothrombotic markers versus healthy controls.
Why the study?
Diabetic patients exhibit a hypercoagulable state that may contribute to vascular complications, but the interaction between Lp(a) and coagulation-fibrinolytic parameters in diabetic nephropathy is not fully understood.
Comparison
Diabetic patients with nephropathy vs diabetic patients without nephropathy and healthy controls
Design
Cross-sectional study
Authors
Loading...
May link Lp(a) to diabetic hypercoagulability; hypothesis-generating and requires prospective validation.
Cross-Sectional (n=135)
No
p-value: p=<0.05
Elevated Lp(a) correlates with markers of hypercoagulability (alpha 2PIC and TAT) in diabetic patients with nephropathy, suggesting a mechanism for increased vascular complications in this population.
Takashi Nagai (1994) conducted a cross-sectional in Diabetes mellitus with nephropathy (n=135). Diabetes with nephropathy vs. Healthy non-diabetic controls was evaluated on Plasma levels of Lipoprotein (a) (p=<0.05). Diabetic patients with nephropathy had significantly elevated plasma levels of Lipoprotein (a) (p<0.05), thrombin-antithrombin III complex (p<0.01), and alpha2 plasmin inhibitor-plasmin complex (p<0.05) compared to healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: